Daiwa Securities Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$402K Buy
767
+699
+1,028% +$334K ﹤0.01% 946
2025
Q4
$40K Sell
68
-2
-3% -$1.02K ﹤0.01% 1132
2025
Q3
$32K Sell
70
-7
-9% -$2.61K ﹤0.01% 1118
2025
Q2
$23K Buy
77
+5
+7% +$1.49K ﹤0.01% 1095
2025
Q1
$24K Hold
72
﹤0.01% 1065
2024
Q4
$22K Sell
72
-11
-13% -$3.09K ﹤0.01% 1084
2024
Q3
$18K Buy
83
+9
+12% +$2.3K ﹤0.01% 1104
2024
Q2
$21K Hold
74
﹤0.01% 1132
2024
Q1
$20K Sell
74
-7
-9% -$1.65K ﹤0.01% 1137
2023
Q4
$19K Buy
81
+12
+17% +$2.1K ﹤0.01% 1130
2023
Q3
$10K Hold
69
﹤0.01% 1125
2023
Q2
$16K Hold
69
﹤0.01% 1114
2023
Q1
$17K Hold
69
﹤0.01% 1084
2022
Q4
$20K Buy
69
+12
+21% +$1.17K ﹤0.01% 1082
2022
Q3
$4K Hold
57
﹤0.01% 1177
2022
Q2
$4K Hold
57
﹤0.01% 1184
2022
Q1
$6K Hold
57
﹤0.01% 1161
2021
Q4
$5K Hold
57
﹤0.01% 1200
2021
Q3
$5K Buy
57
+28
+97% +$2.42K ﹤0.01% 1177
2021
Q2
$3K Hold
29
﹤0.01% 1112
2021
Q1
$3K Hold
29
﹤0.01% 1111
2020
Q4
$3K Buy
+29
New +$3.54K ﹤0.01% 1090

Other funds holding MDGL

Daiwa Securities Group's MDGL Position: Q1 2026 in Review

Daiwa Securities Group increased its Madrigal Pharmaceuticals (MDGL) stake by 1,028% in Q1 2026, buying an estimated $334K and bringing the position to 767 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Daiwa Securities Group first reported a position in MDGL in Q4 2020 and has held it in 22 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Daiwa Securities Group held 767 shares of Madrigal Pharmaceuticals worth $402K as of Q1 2026.
  • Daiwa Securities Group bought 699 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $334K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #946 holding.
  • Daiwa Securities Group first reported a position in Madrigal Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.